BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 17355741)

  • 1. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
    Yildirim N; Sahin A; Gultekin S
    J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
    Aptel F; Cucherat M; Denis P
    J Glaucoma; 2008 Dec; 17(8):667-73. PubMed ID: 19092464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
    García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
    Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination.
    Centofanti M; Oddone F; Gandolfi S; Hommer A; Boehm A; Tanga L; Sangermani C; Sportelli V; Haustein M; Manni G; Rossetti L
    Am J Ophthalmol; 2010 Oct; 150(4):575-80. PubMed ID: 20688314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ; Walt JG
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension.
    Orme M; Collins S; Dakin H; Kelly S; Loftus J
    Curr Med Res Opin; 2010 Mar; 26(3):511-28. PubMed ID: 20014995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.
    Koz OG; Ozsoy A; Yarangumeli A; Kose SK; Kural G
    Acta Ophthalmol Scand; 2007 Dec; 85(8):838-43. PubMed ID: 17680841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2005 Nov; 21(11):1875-83. PubMed ID: 16307709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization.
    Law SK; Song BJ; Fang E; Caprioli J
    Ophthalmology; 2005 Dec; 112(12):2123-30. PubMed ID: 16225924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
    Konstas AG; Katsimbris JM; Lallos N; Boukaras GP; Jenkins JN; Stewart WC
    Ophthalmology; 2005 Feb; 112(2):262-6. PubMed ID: 15691561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma.
    Cheng JW; Cai JP; Li Y; Wei RL
    J Glaucoma; 2009 Dec; 18(9):652-7. PubMed ID: 20010242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma.
    Quaranta L; Pizzolante T; Riva I; Haidich AB; Konstas AG; Stewart WC
    Br J Ophthalmol; 2008 Sep; 92(9):1227-31. PubMed ID: 18586898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.